Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
Osmotica Pharmaceuticals (Nasdaq: OSMT) is set to announce its first quarter 2021 financial results on May 13, 2021, after U.S. market close. CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn will conduct a conference call at 4:30 p.m. ET. Investors can access the call via a toll-free number or through the company's website for a live and replay webcast. Osmotica specializes in biopharmaceuticals aimed at underserved patient populations, with operations in the U.S., Argentina, and Hungary.
- Upcoming financial results announcement may provide insights into company performance.
- CEO and executive team engagement through a conference call enhances transparency.
- None.
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Thursday, May 13, 2021 |
| Time | 4:30 p.m. ET |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |
| Conference ID | 6588774 |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Osmotica Pharmaceuticals release its first quarter 2021 financial results?
What time is the Osmotica conference call for financial results?
How can I access the Osmotica Pharmaceuticals conference call?
What is the focus of Osmotica Pharmaceuticals?
